CDTRP 2023 Research Innovation Grant Competition Results

CDTRP is thrilled to announce the results of the CDTRP 2023 Research Innovation Grant Competition, made possible through our partnership with various esteemed organizations. We are proud to showcase all of the exciting projects that have been funded in this year’s competition.

We would like to extend our warmest congratulations to Dr. James Lan and his team for being awarded the Transplant Research Foundation of BC/CDTRP Venture Grant. We wish them all the best as they embark on their innovative project!

“The Transplant Research Foundation of BC is thrilled to support such a wide depth and breadth of research that will lead to important new discoveries to truly transform organ donation and transplantation in British Columbia and Canada.”

– Elaine Yong, TRFBC Co-Chair

Transplant Research Foundation of BC/CDTRP Venture Grant: Dr. James Lan

Accelerating the Translation of a Novel Luminex Anti-ABO Antibody Detection Technology to Expand the Use of ABO-Incompatible Transplantation in Canada 

  • Main affiliation: University of British Columbia
  • Theme 3 – Engineer and Allocate Better Grafts
Lay abstract

Although kidney transplantation offers better patient survival and quality of life over dialysis treatment, many patients on the transplant wait-list have a hard time finding a match due to their blood type. The ABO blood group of a patient is one of the most important factors that determines their ability to find a match. In Canada, patients that are blood group B and O experience much longer transplant wait-times compared to patients with other blood groups (A and AB). To overcome this problem, doctors can perform transplantation across blood groups (ABO incompatible transplantation) to help difficult to match patients. However, this approach is not used widely as it can increase the risk of rejection. This is because doctors cannot reliably tell based on the current lab test which patients are safe to transplant across the ABO blood group. In a breakthrough development, our research group developed a new lab test (Luminex method) which can better assess the risk of rejection in patients that choose to receive an ABO-incompatible transplant. In this research, we will apply the Luminex test to understand why some patients develop rejection when they receive an ABO-incompatible transplant while others don’t. In addition, we will test blood samples from patients on the current transplant wait-list to advise clinicians whether ABO-incompatible transplantation is a good treatment option. This research is innovative as it has the potential to safely allow for transplants that would previously not occur and greatly expand the transplant opportunities for patients awaiting a kidney transplant.